Overview

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2024-09-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Carboplatin
Etoposide
Nivolumab